%0 Journal Article %1 Wang2005 %A Wang, Y %A Klijn, J G %A Zhang, Y %A Sieuwerts, A M %A Look, M P %A Yang, F %A Talantov, D %A Timmermans, M %A Meijer-van Gelder, M E %A Yu, J %A Jatkoe, T %A Berns, E M %A Atkins, D %A Foekens, J A %D 2005 %J Lancet %K breast cancer data %N 9460 %P 671-679 %R 10.1016/S0140-6736(05)17947-1 %T Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer %U http://www.ncbi.nlm.nih.gov/pubmed/15721472 %V 365 %X Genome-wide measures of gene expression can identify patterns of gene activity that subclassify tumours and might provide a better means than is currently available for individual risk assessment in patients with lymph-node-negative breast cancer.We analysed, with Affymetrix Human U133a GeneChips, the expression of 22000 transcripts from total RNA of frozen tumour samples from 286 lymph-node-negative patients who had not received adjuvant systemic treatment.In a training set of 115 tumours, we identified a 76-gene signature consisting of 60 genes for patients positive for oestrogen receptors (ER) and 16 genes for ER-negative patients. This signature showed 93% sensitivity and 48% specificity in a subsequent independent testing set of 171 lymph-node-negative patients. The gene profile was highly informative in identifying patients who developed distant metastases within 5 years (hazard ratio 5.67 95% CI 2.59-12.4), even when corrected for traditional prognostic factors in multivariate analysis (5.55 2.46-12.5). The 76-gene profile also represented a strong prognostic factor for the development of metastasis in the subgroups of 84 premenopausal patients (9.60 2.28-40.5), 87 postmenopausal patients (4.04 1.57-10.4), and 79 patients with tumours of 10-20 mm (14.1 3.34-59.2), a group of patients for whom prediction of prognosis is especially difficult.The identified signature provides a powerful tool for identification of patients at high risk of distant recurrence. The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options.

@article{Wang2005, abstract = {Genome-wide measures of gene expression can identify patterns of gene activity that subclassify tumours and might provide a better means than is currently available for individual risk assessment in patients with lymph-node-negative breast cancer.We analysed, with Affymetrix Human U133a GeneChips, the expression of 22000 transcripts from total RNA of frozen tumour samples from 286 lymph-node-negative patients who had not received adjuvant systemic treatment.In a training set of 115 tumours, we identified a 76-gene signature consisting of 60 genes for patients positive for oestrogen receptors (ER) and 16 genes for ER-negative patients. This signature showed 93% sensitivity and 48% specificity in a subsequent independent testing set of 171 lymph-node-negative patients. The gene profile was highly informative in identifying patients who developed distant metastases within 5 years (hazard ratio 5.67 [95% CI 2.59-12.4]), even when corrected for traditional prognostic factors in multivariate analysis (5.55 [2.46-12.5]). The 76-gene profile also represented a strong prognostic factor for the development of metastasis in the subgroups of 84 premenopausal patients (9.60 [2.28-40.5]), 87 postmenopausal patients (4.04 [1.57-10.4]), and 79 patients with tumours of 10-20 mm (14.1 [3.34-59.2]), a group of patients for whom prediction of prognosis is especially difficult.The identified signature provides a powerful tool for identification of patients at high risk of distant recurrence. The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options.}, added-at = {2012-09-15T11:23:13.000+0200}, author = {Wang, Y and Klijn, J G and Zhang, Y and Sieuwerts, A M and Look, M P and Yang, F and Talantov, D and Timmermans, M and Meijer-van Gelder, M E and Yu, J and Jatkoe, T and Berns, E M and Atkins, D and Foekens, J A}, biburl = {https://www.bibsonomy.org/bibtex/2ce1e1fb68538aa879a6c52f6895468e7/sbsad}, description = {Gene-expression profiles to predict distant... [Lancet. 2005 Feb 19-25] - PubMed - NCBI}, doi = {10.1016/S0140-6736(05)17947-1}, groups = {public}, interhash = {459ed16fe2fdae999729d7b1242ecbeb}, intrahash = {ce1e1fb68538aa879a6c52f6895468e7}, journal = {Lancet}, keywords = {breast cancer data}, month = {February}, number = 9460, pages = {671-679}, pmid = {15721472}, timestamp = {2012-09-18T11:17:55.000+0200}, title = {Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer}, url = {http://www.ncbi.nlm.nih.gov/pubmed/15721472}, username = {sbsad}, volume = 365, year = 2005 }